Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAP NASDAQ:ANL NASDAQ:IZTC NASDAQ:KPTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.06-1.9%$0.16$0.05▼$1.32$15.61M2.2481.12 million shs25.06 million shsANLAdlai Nortye$1.79+5.9%$1.58$1.10▼$3.89$62.36M-0.948,305 shs5,121 shsIZTCInvizyne Technologies$9.70$9.84$8.50▼$23.00$60.64MN/A37,647 shs325 shsKPTIKaryopharm Therapeutics$6.78-4.6%$4.91$3.51▼$16.95$58.79M0.35216,596 shs126,497 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics-1.87%-0.34%-27.66%-79.73%-95.45%ANLAdlai Nortye+5.92%+7.83%+23.02%+5.29%-36.75%IZTCInvizyne Technologies0.00%+4.19%-3.72%-28.15%+969,999,900.00%KPTIKaryopharm Therapeutics-4.64%-9.12%+72.52%+56.22%-40.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAPAdaptimmune Therapeutics1.9166 of 5 stars3.03.00.00.02.51.70.0ANLAdlai Nortye1.6965 of 5 stars3.03.00.00.03.30.00.0IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AKPTIKaryopharm Therapeutics3.9737 of 5 stars3.40.00.04.63.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 2.00Hold$1.352,238.52% UpsideANLAdlai Nortye 2.00Hold$9.00402.79% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/AKPTIKaryopharm Therapeutics 2.80Moderate Buy$34.00401.47% UpsideCurrent Analyst Ratings BreakdownLatest ADAP, ANL, KPTI, and IZTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$42.00 ➝ $25.007/29/2025ADAPAdaptimmune TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/29/2025ADAPAdaptimmune TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral7/16/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral7/11/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$27.006/26/2025ADAPAdaptimmune TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$1.50 ➝ $0.50(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$178.03M0.09N/AN/A($0.27) per share-0.21ANLAdlai Nortye$5M13.21N/AN/A$0.69 per share2.59IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AKPTIKaryopharm Therapeutics$137.27M0.43N/AN/A($27.55) per share-0.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$70.81M-$0.65N/AN/AN/A-260.82%-163.73%-75.83%11/12/2025 (Estimated)ANLAdlai Nortye-$51.87MN/A0.00N/AN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AKPTIKaryopharm Therapeutics-$76.42M-$14.59N/AN/AN/A-90.02%N/A-84.28%11/4/2025 (Estimated)Latest ADAP, ANL, KPTI, and IZTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ADAPAdaptimmune Therapeutics-$0.15-$0.11+$0.04-$0.11$11.04 million$13.68 million8/11/2025Q2 2025KPTIKaryopharm Therapeutics-$3.80-$4.32-$0.52-$4.32$37.92 million$37.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/AANLAdlai NortyeN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune Therapeutics4.241.521.29ANLAdlai Nortye0.021.411.41IZTCInvizyne TechnologiesN/AN/AN/AKPTIKaryopharm TherapeuticsN/A0.990.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%ANLAdlai Nortye35.21%IZTCInvizyne TechnologiesN/AKPTIKaryopharm Therapeutics66.44%Insider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.44%ANLAdlai NortyeN/AIZTCInvizyne TechnologiesN/AKPTIKaryopharm Therapeutics2.75%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490265.05 million232.08 millionOptionableANLAdlai Nortye12736.90 millionN/ANot OptionableIZTCInvizyne Technologies296.25 millionN/AN/AKPTIKaryopharm Therapeutics3808.67 million8.43 millionOptionableADAP, ANL, KPTI, and IZTC HeadlinesRecent News About These CompaniesKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2 at 4:05 PM | prnewswire.com139,646 Shares in Karyopharm Therapeutics Inc. $KPTI Acquired by T. Rowe Price Investment Management Inc.August 28, 2025 | marketbeat.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Recommendation of "Moderate Buy" from BrokeragesAugust 23, 2025 | marketbeat.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comKaryopharm’s Earnings Call: Clinical Wins Amid Financial StrainAugust 13, 2025 | msn.comKaryopharm Therapeutics Inc.: Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company ProgressAugust 12, 2025 | finanznachrichten.deKaryopharm Therapeutics: Q2 Earnings SnapshotAugust 12, 2025 | chron.comKaryopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue EstimatesAugust 11, 2025 | zacks.comKaryopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call TranscriptAugust 11, 2025 | seekingalpha.comKaryopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company ProgressAugust 11, 2025 | prnewswire.comKaryopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Report Preview: What To ExpectAugust 10, 2025 | finance.yahoo.comEarnings Outlook For Karyopharm TherapeuticsAugust 8, 2025 | benzinga.comKaryopharm to Report Second Quarter 2025 Financial Results on August 11, 2025August 5, 2025 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | prnewswire.comKaryopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseJuly 29, 2025 | zacks.comJPMorgan Chase & Co. Expands Stake in Karyopharm Therapeutics Inc.July 22, 2025 | gurufocus.comHC Wainwright & Co. Downgrades Karyopharm Therapeutics (KPTI)July 16, 2025 | msn.comKaryopharm stock tumbles after disclosing failed financing talksJuly 11, 2025 | investing.comKaryopharm lays off more workers as hunt for strategic alternatives turns up shortJuly 11, 2025 | fiercebiotech.comFKaryopharm Shares Slide After Financing Efforts Stall, Strategic Review UnderwayJuly 11, 2025 | msn.comKaryopharm to Cut About 20% of Workforce Amid Ongoing ReviewJuly 11, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Tempus AI’s Strong Q2 Fuels Growth Story—More Upside Ahead?By Leo Miller | August 13, 2025ADAP, ANL, KPTI, and IZTC Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAP$0.06 0.00 (-5.09%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Adlai Nortye NASDAQ:ANL$1.76 +0.07 (+4.44%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Invizyne Technologies NASDAQ:IZTC$9.70 0.00 (0.00%) As of 08/29/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.Karyopharm Therapeutics NASDAQ:KPTI$6.63 -0.48 (-6.77%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers Tesla Bulls Need to Tread Very Carefully Right Now Amazon Faces Rare Downgrade—Is the Rally at Risk? What to Watch for From D-Wave Now That Earnings Are Done Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
